Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leiner Plans Suit Against Dr. Reddy’s, Expects Delay Restarting OTC Business

This article was originally published in The Tan Sheet

Executive Summary

Leiner Health Products' restart of its U.S. OTC operations could be delayed due to the loss of an exclusive ingredient supply contract with Dr. Reddy's Laboratories, the Carson, Calif.-based firm says

You may also be interested in...



Leiner Files For Chapter 11 Protection, Explores Selling Business

Leiner Health Products' shutdown of its U.S. OTC operations a year ago forced the firm to seek Chapter 11 bankruptcy protection and explore selling its U.S. business

Leiner Files For Chapter 11 Protection, Explores Selling Business

Leiner Health Products' shutdown of its U.S. OTC operations a year ago forced the firm to seek Chapter 11 bankruptcy protection and explore selling its U.S. business

Plethico’s Natrol Acquisition Reflects Growing Indian Supplement Investment

Plethico Pharmaceuticals' $80.8 million acquisition of Natrol could be a bellwether of Indian firms' interest in growing their presence in the U.S. supplement market

Related Content

Topics

UsernamePublicRestriction

Register

PS100664

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel